Accellix, Inc. Announces the Appointment of Nir Nimrodi as Chairman and Chief Executive Officer. Nimrodi Will Lead the Company’s Accelerated Growth as It Launches Custom and Standardized Panel Assays to Be Used by Its Expanding Installed Base.

SAN JOSE, Calif. & JERUSALEM--(BUSINESS WIRE)--Accellix, Inc. is pleased to announce the appointment of Nir Nimrodi as Chairman and Chief Executive Officer effective immediately. Mr. Nimrodi has served as the Executive Chairman of Accellix since June 2019.

Mr. Nimrodi commented, “I joined Accellix as Executive Chairman in June of 2019, and after seven months of significant growth, the board and I decided that I needed to be more deeply involved in support of our continuous growth in the cell and gene therapy market.”

In order to serve its growing list of customers in the cell and gene therapy market, Accellix has recently launched standardized kits such as the T-Cell and Lymphocyte Subset Assays to provide immediate fixed panels for common markers. These assays are in addition to the growing number of customized assay kits available to Accellix’s global customers.

Mr. Nimrodi brings 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical and biotechnology industries. In his most recent role, Nir served as the Chief Business Officer of Intrexon Corporation, the global leader in synthetic biology. Intrexon and its partners are among the pioneering companies in the field of immuno-oncology as well as several other gene therapy programs.

Prior to Intrexon, Nir held several executive roles at Life Technologies (now part of Thermo Fisher). While at Life, Nir served as Chief Executive Officer and Board Member of Life Technologies Israel, Head of Protein Technologies, as well as Vice President and General Manager of Food Safety and Animal Health. Prior to his 7 years at Life Technologies, he was the CEO of Proneuron Biotechnologies and Mindsense Biosystems. Earlier in his career, Nir was a Director of Finance for Teva Pharmaceuticals.

About Accellix: Accellix is a biotechnology company dedicated to developing and commercializing the Accellix platform to enable its customers in the field of cell and gene therapy to meet their critical QC requirements as they advance life changing therapies benefiting patients worldwide. Accellix empowers its customers by migrating their existing cell assays to the Accellix platform. The Accellix platform is a benchtop cytometer operating and reading capillary cartridges integrated with dry reagents. It provides unmatched reproducibility and ease of use for automated multi-parametric cell analysis. For more information visit www.accellix.com